Lanthanum carbonate is a phosphate binder indicated for the reduction of serum phosphate in patients with end-stage renal disease. Lanthanum carbonate is a phosphate binder marketed under the trade name Fosrenol by Shire Pharmaceuticals.
- Mechanism
- Curator reviewed · 1 reference
Lanthanum carbonate is a phosphate binder that reduces absorption of phosphate by forming insoluble lanthanum phosphate complexes that pass through the gastrointestinal (GI) tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.
- Primary indication
- Lanthanum carbonate is indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD).Curator reviewed · 1 structured indication
- Formula / weight
- C3La2O9 · 457.835 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2004
- Also known as
- Lanthanum (III) carbonate · Lanthanum sesquicarbonate · Lanthanum(3+) carbonate
- Brand names
Resolves to
NZPIUJUFIFZSPW-UHFFFAOYSA-HSMILES[La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=OWhat you can answer from here — as of August 30, 2026
Which other approved drugs treat the same conditions as Lanthanum carbonate, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account